Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma
- PMID: 19165071
- DOI: 10.1227/01.NEU.0000339118.55334.EA
Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma
Abstract
Objective: To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for patients with brain metastases of malignant melanoma and renal cell carcinoma.
Methods: We conducted a retrospective review of all patients treated by image-guided radiosurgery at our institution between March 1999 and December 2005. Sixty-two patients with 145 brain metastases of renal cell carcinoma or melanoma were identified.
Results: The median follow-up period was 10.5 months. Forty-four patients had malignant melanoma, and 18 patients had renal cell carcinoma. The median age was 57 years, and patients were classified as recursive partitioning analysis Class 1 (6 patients), 2 (52 patients) or 3 (4 patients). Thirty-three patients had been treated systemically with either chemotherapy or immunotherapy, and 33 patients were taking corticosteroids at the time of treatment. The mean tumor volume was 1.47 mL (range, 0.02-35.7 mL), and the mean prescribed dose was 20 Gy (range, 14-24 Gy). The median survival after SRS was 8.3 months. Actuarial survival at 6 and 12 months was 57 and 37%, respectively. On multivariate analysis, Karnofsky Performance Scale score (P < 0.01) and previous immunotherapy/clinical trial (P = 0.01) significantly affected overall survival. One-year intracranial progression-free survival was 38%, and local control was 87%. Intracranial control was impacted by whole-brain radiotherapy (P = 0.01), previous chemotherapy (P = 0.01), and control of the primary at the time of SRS (P = 0.02). Surgical resection had no effect on intracranial or local control. Radiographic evidence of radiation necrosis developed in 4 patients (6%).
Conclusion: CyberKnife radiosurgery provided excellent local control with acceptable toxicity in patients with melanoma or renal cell brain metastases. Initial SRS alone appeared to be a reasonable option, as survival was dictated by systemic disease.
Similar articles
-
Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery.Neurosurgery. 2005 May;56(5):936-45; discussion 936-45. Neurosurgery. 2005. PMID: 15854241
-
Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).Cancer. 2007 May 1;109(9):1855-62. doi: 10.1002/cncr.22605. Cancer. 2007. PMID: 17351953
-
Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1097-106. doi: 10.1016/j.ijrobp.2003.12.037. Int J Radiat Oncol Biol Phys. 2004. PMID: 15234044
-
Radiosurgery for the treatment of brain metastases in renal cell carcinoma.Anticancer Res. 1999 Mar-Apr;19(2C):1611-7. Anticancer Res. 1999. PMID: 10365156 Review.
-
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):37-46. doi: 10.1016/j.ijrobp.2005.05.023. Int J Radiat Oncol Biol Phys. 2005. PMID: 16111570 Review.
Cited by
-
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.Radiat Oncol. 2011 Apr 8;6:34. doi: 10.1186/1748-717X-6-34. Radiat Oncol. 2011. PMID: 21477295 Free PMC article.
-
Salvage robot-assisted partial nephrectomy for the management of renal cell carcinoma following failed stereotactic radiotherapy.JSLS. 2012 Jan-Mar;16(1):159-62. doi: 10.4293/108680812X13291597716988. JSLS. 2012. PMID: 22906347 Free PMC article.
-
Stereotactic radiosurgery for brain metastases from malignant melanoma.Surg Neurol Int. 2015 Aug 20;6(Suppl 12):S355-65. doi: 10.4103/2152-7806.163315. eCollection 2015. Surg Neurol Int. 2015. PMID: 26392919 Free PMC article.
-
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.Curr Treat Options Oncol. 2023 Dec;24(12):1962-1977. doi: 10.1007/s11864-023-01155-3. Epub 2023 Dec 30. Curr Treat Options Oncol. 2023. PMID: 38158477 Review.
-
Efficacy, safety and outcome of frameless image-guided robotic radiosurgery for brain metastases after whole brain radiotherapy.J Neurooncol. 2018 May;138(1):73-81. doi: 10.1007/s11060-018-2771-2. Epub 2018 Jan 29. J Neurooncol. 2018. PMID: 29376195
MeSH terms
LinkOut - more resources
Full Text Sources
Medical